High-performance polymer films specialist, Renolit, has announced its participation in the series A funding round of the Munich-based start-up and 3D printing system developer, Kumovis.
Kumovis co-founders: Stefan Leonhardt, Dr Miriam Haerst, Alexander Henhammer, Sebastian Pammer, Stefan Fischer (from left to right)
Renolit is participating alongside Solvay and the two seed investors - the High-Tech Gründerfonds and Ffilipa Venture Capital. Renolit will be the unique strategic healthcare investor of Kumovis, a company who focuses on entering new markets, accelerating growth, and enabling medical device manufacturers to ensure the full potential of high-performance polymers. Kumovis has raised €3.6 million in the Series A funding round.
Thomas Sampers, who leads Renolit Healthcare, commented: “This investment is a further major step for Renolit Healthcare fostering its innovative dynamics towards health together with partners, by reinforcing its presence in polymer based healthcare devices with new innovative technologies and devices, as well as new business models.”
Stefan Leonhardt, co-CEO and co-founder of Kumovis, said: “The launch of the Kumovis R1 3D printer in 2019 pushed additive manufacturing with medical polymers to the next level regarding mechanical properties, aesthetic, reproducibility and usability.
"We are convinced that partnership with Renolit, leader in polymer based medical device components, will strengthen our business case and accelerate the development of Kumovis. The investment will be used to enter new markets, further develop our technology and help to bring 3D printed medical products to the patient.”
Dr. Miriam Haerst, also co-CEO and co-founder of Kumovis, added: “The flexibility of our 3D printing system, which fulfills all medical manufacturing requirements, is particularly advantageous when it comes to small-series production or patient-individualised products. Thanks to the technology, production can be located at optimal location along the value chain, and in particular right at point of care. This allows the shortening of the supply chain and thus also the time to patient.”
Pierre Winant, Renolit representative in the board of directors of the start-up, concluded: “I am looking forward to support the young talented dynamic team of Kumovis which I am convinced will benefit of the expertise and competences of Renolit in healthcare.”